
India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears
Dr Reddy’s Laboratories logged its steepest weekly loss in three years on Friday, after a disruption in generic semaglutide supply raised concerns it could lose its edge in the highly competitive diabetes market.

































.jpg)


































_20260101112329999_0153db_20260209062258909_9180ec.webp)















